CLIA Change of Ownership: Buying an Existing Lab
A CLIA change of ownership is one of the most important practical issues in any laboratory acquisition. When a certified lab is sold, the buyer needs to know whether testing can continue without interruption, which notices and applications are required and how long claims may be delayed while payer enrollments are updated. Those answers affect the deal structure, the purchase agreement and the financing.
This article explains, from a financing perspective, how change-of-ownership issues shape a lab purchase. Certification, licensure and enrollment rules vary by state and payer and change over time, and nothing here is legal, regulatory, billing or compliance advice. Buyers should rely on healthcare counsel and qualified compliance professionals for their specific transaction.
Why a CLIA Change of Ownership Matters to Buyers
A lab’s ability to generate revenue depends on several approvals working together: its CLIA certificate, any state license, accreditation if applicable, Medicare and Medicaid enrollment and commercial insurer contracts. None of these should be assumed to transfer automatically when ownership changes.
If any piece is not updated correctly, the lab may face gaps in its ability to test, bill or get paid. For a buyer who is also taking on acquisition debt, even a temporary pause in collections can create real pressure.
Asset Purchase vs. Equity Purchase
The structure of the transaction can change what the change-of-ownership process looks like.
In an asset purchase, the buyer acquires the lab’s equipment, client relationships and other assets, typically through a new or different legal entity. Certificates, licenses and payer enrollments may need to be updated or newly obtained in the buyer’s name. The buyer may avoid some historical liabilities, but the transition can be more involved.
In an equity purchase, the buyer acquires the ownership interests of the entity that operates the lab. The entity, its certificate and its enrollments may remain in place, but notices of the ownership change are still generally required. The buyer also inherits the entity’s history, including any billing or compliance issues.
Medicare enrollment rules can also affect liability. Depending on how enrollment is handled, a buyer may become responsible for overpayments or other obligations that arose before closing. Healthcare counsel should explain those consequences before the structure is chosen.
What the Process Typically Involves
While each transaction is different, a CLIA change of ownership often requires:
- Notifying the state agency of the change in ownership within the required period
- Updating the certificate with new ownership, entity or director information
- Notifying the accreditation organization, if the lab is accredited
- Updating or obtaining a state laboratory license where required
- Filing Medicare and Medicaid enrollment updates or new applications
- Notifying commercial insurers and reviewing contract assignment terms
- Confirming the laboratory director will remain or arranging a qualified replacement
The laboratory director is especially important. If the director leaves at closing, the lab may need to name and qualify a new director before testing can continue.
How Change of Ownership Affects Financing
Lenders financing a lab acquisition generally want to understand the change-of-ownership plan before closing. They may ask:
- Is the deal structured as an asset or equity purchase, and why?
- Which certificates, licenses and enrollments must be updated?
- Will claims be delayed, and for how long might the lab rely on reserves?
- Will the current director stay through the transition?
- What liabilities might transfer with the entity or the enrollment?
Because claims can be held while enrollments are processed, buyers often include working capital in the financing request. Our lab working capital and lines of credit page explains options for bridging that period.
SBA 7(a) loans may be used to finance the acquisition of an existing business and related working capital. Eligibility and terms depend on the business, the buyer, use of proceeds, program rules and lender review, and every loan is subject to approval.
Due Diligence Before a CLIA Change of Ownership
Before signing, buyers should review:
- The current certificate type, specialties and expiration date
- Recent inspection reports and any deficiencies or plans of correction
- Proficiency testing results and any unsuccessful events
- State license status and inspection history
- Payer enrollment details and any revalidation deadlines
- Billing audits, recoupments and repayment arrangements
- The director’s agreement and willingness to remain
These items should be reviewed by healthcare counsel and qualified compliance professionals. Specialty labs may require deeper review; our article on buying a toxicology lab explains why.
Building the Purchase Agreement Around the Transition
The purchase agreement can address change-of-ownership risks through closing conditions, seller cooperation obligations, transition services, escrows and indemnities. A seller transition period can help keep clients, staff and the director in place while approvals are updated.
Buyers should also plan client communication. Physician offices and facilities that send specimens may need updated requisitions, billing information and interface settings. Clear, early communication can reduce the risk that clients redirect specimens to a competitor while the change of ownership is underway.
For an overview of the full acquisition process, including valuation and deal structure, see our guide on how to buy a clinical laboratory.
Final Thoughts
A CLIA change of ownership is not a formality. It shapes the deal structure, the liabilities a buyer may assume, the timing of collections and the amount of working capital the buyer needs. Planning it early, with counsel and your lender, can help keep testing and cash flow on track after closing.
US Medical Funding helps buyers finance laboratory acquisitions, including transition working capital. Learn more about our lab and pathology acquisition financing and our full range of laboratory and pathology financing options.
